Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University, Heidelberg, Germany.
Retina. 2010 Oct;30(9):1426-31. doi: 10.1097/IAE.0b013e3181d5e964.
The purpose of this study was to assess an association between specific types of subfoveal neovascularization and the change in visual acuity after intravitreal injections of bevacizumab (F. Hoffmann-La Roche AG, Basel, Switzerland) as treatment for exudative age-related macular degeneration.
This retrospective clinical interventional comparative study included 307 patients (378 eyes) who received 3 consecutive intravitreal injections of bevacizumab at intervals of 2 months each. The study group was divided into eyes with a predominantly or purely classic type of subfoveal neovascular membrane (n = 81), those with an occult type with or without minimally classic subfoveal neovascularization (n = 232), and eyes with a detachment of the retinal pigment epithelium (n = 65).
The gain in best-corrected visual acuity did not vary significantly among the 3 subgroups at 2 months after baseline (P = 0.35 and P = 0.27), at 4 months after baseline (P = 0.63 and P = 0.56), or at the final follow-up at 7 months after baseline (P = 0.85 and P = 0.76). In multivariate linear regression analysis, the gain in best-corrected visual acuity at the final follow-up was significantly associated with the best-corrected visual acuity at baseline (P < 0.001). It was not significantly associated with age (P = 0.61), sex (P = 0.12), self-reported diabetes (P = 0.79), lens status (P = 0.84), or type of subfoveal neovascularization (P = 0.53).
After an intravitreal application of bevacizumab given as therapy for exudative age-related macular degeneration at 2-month intervals, the patient's gain in visual acuity did not depend on the type of the subfoveal neovascular membranes.
本研究旨在评估特定位点的黄斑下新生血管与玻璃体内注射贝伐单抗（罗氏制药，巴塞尔，瑞士）治疗渗出性年龄相关性黄斑变性后视力变化之间的相关性。
这是一项回顾性临床干预性对比研究，共纳入 307 例（378 只眼）患者，每 2 个月接受 3 次连续的玻璃体内贝伐单抗注射。研究组根据黄斑下新生血管膜的主要或纯经典型（n = 81）、隐匿型伴或不伴最小经典型黄斑下新生血管化（n = 232）和视网膜色素上皮脱离（n = 65）进行分组。
在基线后 2 个月（P = 0.35 和 P = 0.27）、基线后 4 个月（P = 0.63 和 P = 0.56）和最终随访时（基线后 7 个月，P = 0.85 和 P = 0.76），3 个亚组之间最佳矫正视力的提高没有显著差异。在多元线性回归分析中，最终随访时最佳矫正视力的提高与基线时的最佳矫正视力显著相关（P < 0.001）。它与年龄（P = 0.61）、性别（P = 0.12）、自我报告的糖尿病（P = 0.79）、晶状体状态（P = 0.84）或黄斑下新生血管类型（P = 0.53）均无显著相关性。
在每 2 个月间隔玻璃体内应用贝伐单抗治疗渗出性年龄相关性黄斑变性后，患者的视力提高与黄斑下新生血管膜的类型无关。
